Research programme: anticancer therapeutics - Hercules PharmaceuticalsAlternative Names: CB 7993113
Latest Information Update: 06 Nov 2015
At a glance
- Originator Hercules Pharmaceuticals
- Mechanism of Action Aryl hydrocarbon receptor antagonists; Cytochrome P-450 enzyme system modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer